Clofoctol
Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria.[1] It has been marketed in France till 2005 under the trade name Octofene and in Italy as Gramplus.
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Rectal (suppository)[1] |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 98%[1] |
Metabolism | Hepatic glucuronidation[1] |
Excretion | Biliary[1] |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.048.739 |
Chemical and physical data | |
Formula | C21H26Cl2O |
Molar mass | 365.34 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
It is only functional against Gram-positive bacteria.[2]
It penetrates into human lung tissue.[3]
Apteeus is developing clofoctol as a potential therapy against SARS-CoV-2.[4][5]
References
- "Gramplus" (in Italian). Studio Medico Torrino. July 25, 2007. Archived from the original on March 8, 2016. Retrieved 2007-08-10.
- Combe J, Simonnet F, Yablonsky F, Simonnet G (1980). "[Clofoctol binding by the bacteria (author's transl)]". J Pharmacol (in French). 11 (4): 411–25. PMID 6782374.
- Danesi R, Gasperini M, Senesi S, Freer G, Angeletti CA, Del Tacca M (1988). "A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay". Drugs Exp Clin Res. 14 (1): 39–43. PMID 3391105.
- "Pasteur Lille obtient 5 M€ de LVMH pour repositionner un ancien médicament, l'Octofene, sur le traitement du Covid" (in French). AEF info. October 13, 2020. Retrieved 2020-10-13.
- "La piste clofoctol. Interview du Pr Xavier Nassif". Jim.fr. 13 September 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.